Filing Flows › Biodesix (BDSX) › Q3 2025
Biodesix (BDSX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 3, 2025
Biodesix (BDSX) reported revenue of $21.8M for the third quarter 2025 (Q3 2025), +20% from a year earlier and +9% from the quarter before. Operating margin was -32.4%, net loss $8.7M (40.0% of revenue).
Biodesix, Q3 2025: revenue $21.8M (+20% year over year), operating margin -32.4%, net loss $8.7M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.8M | +9% | +20% |
| Operating profit | −$7.1M | — | — |
| Net earnings | −$8.7M | — | — |
| Operating cash flow | −$8.9M | — | — |
What changed
Revenue was $21.8M in Q3 2025, up 20% year over year and up 9% from the previous quarter. Diagnostic Tests was the largest line at 91% of revenue. Diagnostic Tests added $2.7M year over year (up 16%), 74% of the total change.
Operating costs exceeded revenue by $7.1M, an operating margin of -32.4%. Total costs grew 8% against revenue growth of 20%. The fastest-growing cost line was Research & development (+17%). The quarter ended with a net loss of $8.7M, narrower than the previous quarter's $11.5M loss.
Operating cash flow was −$8.9M. Non-cash charges added back $1.4M of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $2.6M. Capital expenditures of $48K exceeded it, leaving free cash flow of −$8.9M.
Questions
What was Biodesix's revenue in the third quarter 2025?
Biodesix (BDSX) reported revenue of $21.8M for the third quarter 2025 (Q3 2025), +20% from a year earlier and +9% from the quarter before.
Was Biodesix profitable in the third quarter 2025?
Operating loss was $7.1M (-32.4% of revenue) and net loss $8.7M.
Source: Biodesix 10-Q on SEC EDGAR.